Credit Suisse 15/03/2010 1 Outperform $40.50 12.3%
Following news the company has received FDA approval for Hizentra the broker sees the subcutaneous immunoglobulin (SCIG) market the product is in as being worth as much as US$200m annually in sales.
It also notes the company has first mover advantage in the SCIG market, which should support margins in its view.
With the shares trading at a discount to their five-year average earnings multiple the broker retains its Outperform rating and $40.50 price target.
credit suisse - $40.50, page-24
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$309.60 |
Change
1.795(0.58%) |
Mkt cap ! $149.8B | |||
| Open | High | Low | Value | Volume |
| $310.21 | $311.38 | $309.45 | $42.94M | 138.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 38 | $309.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $309.65 | 58 | 7 |
View Market Depth
| Last trade - 12.34pm 20/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |